

1 **A Double-Blind Placebo-Controlled Trial of Liquid Thyroxine Ingested at Breakfast: Results**
2 **of the TICO study**

3

4 Carlo Cappelli¹, MD, Ilenia Pirola¹, MD, Linda Daffini¹, MD, Annamaria Formenti¹, MD, Carmelo
5 Iacobello², MD, Alessandra Cristiano¹, MD, Elena Gandossi¹, MD, Enrico Agabiti Rosei¹, MD,
6 Maurizio Castellano¹, MD.

7 ¹ Department of Medical and Surgical Sciences, Endocrine and Metabolic Unit, University of
8 Brescia; Clinica Medica – 2^a Medicina Spedali Civili di Brescia

9 ² Department of Molecular and Translational Medicine, University of Brescia, Laboratorio Analisi,
10 AO Spedali Civili di Brescia, Brescia, Italy.

11

12

13 **Running Title:** Liquid Thyroxine Ingested at Breakfast

14 **Key words:** hypothyroidism, levothyroxine treatment, liquid levothyroxine formulation,
15 levothyroxine absorption, drug interactions

16

17

18

19 Address for correspondence:

20 Carlo Cappelli, MD,

21 Department of Medical and Surgical Sciences,

22 Endocrine and Metabolic Unit, University of Brescia c/o 2 Medicina Spedali Civili di Brescia,

23 Piazzale Spedali Civili n°1, 25100 Brescia, Italy,

24 Tel.: ++390303995251, E-mail: cappelli@med.unibs.it

1 **ABSTRACT:**

2 **Background:**

3 Levothyroxine (L-T4) is the recommended treatment for millions of hypothyroid patients. Current guidelines
4 recommend that L-T4 tablets be taken in a fasting state, but inability to adhere to this often leads to poor
5 therapy compliance.

6
7 **Methods:**

8 We conducted a randomized, double-blind, placebo-controlled, crossover trial in previously untreated
9 hypothyroid patients randomly assigned to receive an oral solution of L-T4 either at least 30 minutes before
10 breakfast or directly at breakfast time. Each patient completed two 6-week treatment periods, with different
11 timing of active L-T4 administration: placebo before breakfast and active L-T4 at breakfast, or vice versa. At
12 the end of each period, TSH, fT4 and fT3 were measured. The primary endpoint was to verify any
13 difference in serum TSH levels whether consuming liquid L-T4 at breakfast or 30 minutes prior to breakfast.

14
15 **Results:**

16 A total of 77 patients (64/13 female/male, median age 45.4 ±13.7) completed the study. No statistically
17 significant difference of serum TSH, fT4 and fT3 levels was observed whether L-T4 was taken at breakfast
18 or 30 minutes before, in a fasting state.

19 No significant effect from the sequence of regimens, breakfast composition and/or concomitantly
20 administered drugs was observed on the dose of L-T4 administered, or on the post-treatment serum TSH
21 values.

22
23 **Conclusions:**

24 **The TICO study suggests that a liquid L-T4 formulation can be ingested directly at breakfast, thus**
25 **potentially improving therapeutic compliance.** This observation is of considerable clinical relevance,
26 since non-adherence to L-T4therapy requirements is more likely to cause variability in serum TSH
27 concentrations.

28

1 **INTRODUCTION:**

2 Hypothyroidism is one of the most common chronic disorders worldwide, with prevalences ranging
3 from 0.1 to 2 percent of the population (1-3). Levothyroxine (L-T4) is the treatment of choice and a
4 serum TSH concentration maintained within a narrow range represents the best marker of
5 successful treatment (4,5). The management of hypothyroidism is generally considered
6 straightforward even though cross-sectional surveys of patients taking levothyroxine demonstrate
7 that between 40% and 48% are either over-treated or under-treated (2,6).

8 Different factors may interfere with intestinal absorption of L-T4, including food ingestion, dietary
9 fibre, coffee, drugs, gastric or intestinal resection and diseases, and current guidelines
10 recommend that L-T4 should be taken in a fasting state (4,7).

11 On the other hand, adherence to medical recommendations has been recognized as challenging,
12 especially with regard to drug therapy (8), and a significant number of patients have difficulty
13 complying with L-T4 therapy as they have to postpone their breakfast by 30-60 minutes (9). Over
14 the last few years new, non-tablet L-T4 formulations, such as liquid and soft gel capsules, have
15 been introduced in some countries. Recently, we serendipitously identified hypothyroid patients
16 who maintained euthyroidism despite taking liquid L-T4 contrary to guidelines at breakfast, with
17 their coffee; when the same patients started to ingest the same dose of liquid L-T4 as
18 recommended at least thirty minutes before breakfast, no changes of TSH, free T4 and free T3
19 values were observed (10). To further prospectively evaluate the efficacy of oral liquid L-T4
20 administration at breakfast, we conducted the TICO study (*Tiroxina a COlazione*, translated as
21 “Thyroxine at Breakfast”): a double-blind, placebo-controlled trial, involving naïve hypothyroid
22 patients starting replacement therapy.

1 **Materials and Methods**

2 **Study design and conduct:**

3 The TICO study (EUDRACT registration number: 2013-001696-21) is a randomized, double-blind,
4 placebo-controlled, crossover trial in which previously untreated hypothyroid patients were
5 randomly assigned to receive in the morning an oral solution of L-T4 (Tirosint® fiala monouso,
6 IBSA Farmaceutici Italia). The drug was administered either before breakfast (BEFORE), after an
7 overnight fast and at least 30 minutes prior to food ingestion, or in a fed state directly at breakfast
8 time (AT). The study was approved by an independent Institute Review Board and conducted in
9 accordance with the Declaration of Helsinki and the Good Clinical Practice Guidelines of the
10 International Conference on Harmonisation. All the participants provided prior written informed
11 consent.

12 The study was designed by the investigators and supported by IBSA Farmaceutici Italia. The
13 pharmaceutical company prepared two identical and indistinguishable vials (labeled A and B)
14 containing either a specified dose of L-thyroxine (25, 50, 75 or 100 µg) dissolved in 1 mL solution
15 of 85% glycerol and 96% ethanol (243 mg) or a placebo vehicle control (1 mL of glycerol/ethanol
16 solution).

17 In the morning all patients were given two vials, labeled A and B. The first vial was to be ingested
18 after an overnight fast half an hour before breakfast diluted in a glass of water. Data indicate that
19 gastric emptying after drinking plain water is almost complete within 30 minutes (11), so we can
20 assume that absorption of liquid L-T4 is not influenced by food ingested 30 minutes thereafter. The
21 second vial was ingested during each patient's usual breakfast, mixed with tea, coffee, milk,
22 cappuccino, orange juice, etc. Each patient completed two 6-week regimens, corresponding to the
23 sequence vial A – vial B, or vice versa, with regimens defined by the timing of active L-T4
24 administration: the placebo vial before breakfast and the active L-T4 vial at breakfast (regimen
25 AT=>BEFORE), or vice versa (regimen BEFORE=>AT). Regimen sequence order was
26 randomized according to a permuted blocks allocation scheme (1:1 ratio, with random block size
27 of 2, 4, 6). Placebo or active drug content of vials A and B was determined by the manufacturers

1 at IBSA Farmaceutici and disclosed to the investigators only after study completion and blinded
2 data analysis by the investigators.

3 The intake of drugs potentially interfering with L-T4 absorption (in particular iron or calcium
4 supplements and proton pump inhibitors) was monitored and recorded. In addition, a detailed
5 description of each subject's breakfast composition was obtained, particularly of insoluble fibers
6 and/or soy milk. The study design is shown in Figure 1.

7 The authors assume responsibility for the accuracy of the data and full observance of the study
8 protocol.

9

10 **Study participants:**

11 Patients, aged 18-75 years old, were eligible if they presented symptoms of hypothyroidism and/or
12 TSH values above 10 mIU/L, due to Hashimoto's thyroiditis or thyroidectomy for proven benign
13 goiter. None of the patients had received previous treatment.

14 Subjects with congestive heart failure (NYHA III-IV), coronary heart disease, severe hypertension,
15 uncontrolled diabetes mellitus (HbA1c > 64 mmol/ml) or untreated dyslipidemia were excluded. In
16 order to avoid any possible persistence of TSH elevation in the early phase of pregnancy, women
17 who were pregnant or lactating and women who could possibly become pregnant at any time
18 during the entire study were also excluded. All participants were required to maintain the same
19 breakfast habits and any ongoing therapy for the full duration of the study. The introduction of any
20 additional drugs had to be reported to the researchers.

21 Patient enrollment took place from October 2013 through November 2014.

22 The starting dose of L-T4 was determined through clinical judgment, taking into account TSH
23 levels, estimate of residual thyroid function, age, body weight and comorbidities (4).

24 After the first 6-week regimen all patients were submitted to TSH, fT4 and fT3 evaluation to verify
25 achievement of euthyroidism ($0.2 \leq \text{TSH} \leq 4.2$ mIU/L); if this was not achieved, an appropriately
26 adjusted L-T4 dose was administered for six more weeks and thyroid function parameters re-
27 checked afterwards.

1 When a euthyroid state was reached, the patients had to switch the order in which the vials were
2 ingested and undergo treatment for a second 6-week period. Individual L-T4 doses titrated during
3 the first sequence period did not change during the second sequence. At the end of the second
4 sequence, measurements of TSH, fT4 and fT3 values were repeated and the study was
5 completed. Adherence to protocol requirements (regularity and timing of taking the drugs,
6 unchanged eating habits at breakfast) was assessed by a physician via personal interviews at the
7 end of each regimen period. At the end of the study all patients were formally asked whether they
8 would prefer their daily L-T4 treatment directly at breakfast or 30 to 60 minutes before.

10 **Study endpoints**

11 The primary endpoint was to verify any difference in serum TSH levels (and secondarily in fT4 and
12 fT3) when **ingesting** liquid L-T4 at breakfast compared to 30 minutes earlier.

13 Statistical analysis, based on pilot data from patients taking L-T4 for thyroiditis, indicated that 80
14 subjects would provide 80% power to detect a 20% difference between TSH levels of the two
15 regimen sequences, using a critical significance level of $P=0.05$. In the pilot data, a 20% difference
16 corresponded to 0.6 mIU/L.

18 **Hormone assays**

19 Serum concentrations of free thyroxine (fT4; normal range: 8.0-19.0 pg/mL, analytical sensitivity 1
20 pg/mL), free triiodothyronine (fT3; normal range: 2.4-4.7; analytical sensitivity 0.35 pg/mL), and
21 TSH (normal range: 0.4-4.5 mIU/L, analytical sensitivity 0.004 mIU/L) were measured using a fully
22 automated Architect i2000 analyzer (Abbott Diagnostics, Abbott Park, IL, USA) using
23 chemiluminescent magnetic immunoassays.

25 **Statistical analysis**

26 Data are presented as mean \pm standard deviation for parameters with normal distribution (age,
27 body mass index). Normal distribution was checked by the Shapiro-Wilk test. TSH, fT4 and fT3

1 levels resulted non-normally distributed and were not normalized by the usual procedures of data
2 transformation; in these cases results are presented as median plus range. Comparisons between
3 continuous variables were performed by paired samples t-test or related samples by the Wilcoxon
4 signed rank test, as appropriate. Categorical variables were compared by the χ^2 test. A
5 generalized linear model analysis was performed to examine the influence of potential
6 confounders (for instance, different types of breakfast, dietary supplements or concomitantly
7 administered drugs) on serum TSH levels.

8 Two-tailed $p < 0.05$ was considered statistically significant. Statistical analyses were performed
9 using SPSS 17.0 software (SPSS, Inc., Evanston, IL, USA).

1 RESULTS

2 Ninety-four patients were assessed for eligibility and 86 patients (71/15 female/male, median age
3 46.0 ± 13.8 years) were eligible and enrolled in the study. Nine of 86 patients withdrew from the trial
4 during the first sequence period: in six cases due to non-adherence to protocol requirements and
5 in the remaining three cases for unspecified personal reasons. No patient abandoned the study
6 over the second period of treatment, so that 77 patients (64/13 female/male, median age
7 45.4 ± 13.7) completed the study. Sixty-six patients started replacement therapy for Hashimoto
8 thyroiditis. Eleven patients started replacement therapy after thyroidectomy for the removal of
9 histologically proven benign goiter (details are provided in Supplemental Table 1).

10 After data analysis and blinding disclosure, 38 patients were found to have started the regimen
11 sequence with active L-T4 at breakfast (sequence AT=>BEFORE), while the remaining 39 patients
12 followed the opposite sequence (BEFORE=>AT). Baseline demographic and clinical
13 characteristics according to regimen sequence are shown in Table 1. No difference of age, sex,
14 cause of hypothyroidism and baseline thyroid hormonal profile was observed between the two
15 regimen sequences.

16 After 6 weeks of the first period of treatment, a similar number of patients (32/38, 84%, sequence
17 AT=>BEFORE and 34/39, 87%, sequence BEFORE=>AT) achieved euthyroidism; in the subjects
18 with TSH values still above 4.2 mIU/L, the L-T4 dose was adjusted and treatment continued for six
19 more weeks. All these patients became ultimately euthyroid.

20 The median dose of L-T4 **ingested** by the 77 patients at the end of the first regimen sequence
21 was 75 mcg daily; individual L-T4 doses titrated during the first sequence period were not changed
22 during the second treatment period.

23 No difference of serum TSH, fT4 and fT3 levels was observed irrespective of whether L-T4 was
24 ingested at breakfast or 30 minutes prior in a fasting state. The sequence of regimen
25 (AT=>BEFORE vs BEFORE=>AT) influenced neither the dose of L-T4 administered nor the post-
26 treatment TSH values (Table 2). Similarly, no influence of breakfast composition on TSH and
27 thyroid hormone levels was observed in subgroup analyses, comparing subjects taking a

1 beverage-only breakfast (n=33) vs subjects taking solid foods in addition to beverages (n=44).
2 We purposely did not exclude any patient on concomitant drug treatment (including proton pump
3 inhibitors, calcium or iron supplements) or patients taking fiber and soy milk products at breakfast
4 from the study (Supplemental Table 1). Generalized linear model analysis shows that these and
5 other variables (age, sex, and body weight) had no significant effect on the dose of L-T4
6 administered or the achieved post-treatment TSH values (data not shown). No specific complaints
7 were reported by the patients; in particular, none of the patients noticed changes in the taste of
8 their breakfast. No adverse events were observed by the investigators. All the patients declared
9 they would prefer to take their daily L-T4 treatment directly at breakfast.

1 **DISCUSSION**

2 Current guidelines for the treatment of hypothyroidism by a Task Force of the American Thyroid
3 Association recommend that for optimal and consistent absorption levothyroxine should, if
4 possible, be taken at least 30 minutes before breakfast (or at bedtime, at least three hours after
5 the evening meal) (4). This recommendation is based on a small number of studies indicating that
6 concomitant ingestion of L-T4 with food (12-15), coffee (13) or fiber and soy products (16,17) is
7 associated with higher serum TSH values in hypothyroid subjects, compared to taking L-T4 in the
8 fasting state. However, the Task Force acknowledges that the quality of these studies is only
9 moderate on average and that the strength of the recommendation is weak (4).

10 The recent introduction of non-tablet formulations of L-T4 in the therapeutic environment seems to
11 call this recommendation into question (18). Vita et al. (9) observed in a small number of
12 hypothyroid patients that treatment with a soft gel preparation of L-T4 (Tiche capsules, IBSA
13 Switzerland) is not associated with a reduced absorption of the drug by coffee (14). The same
14 authors observed that the soft gel formulation of L-T4 can also circumvent the problem of
15 incomplete absorption of L-T4 caused by proton pump inhibitor-induced increase of gastric pH
16 (19).

17 Our group first reported on 54 patients who erroneously ingested a liquid L-T4 formulation
18 (Tirosint, IBSA Italy) with coffee: after anticipating the time of liquid L-T4 ingestion to have been 30
19 minutes before breakfast, no change in TSH, fT4, and fT3 concentrations was observed (10). We
20 have also shown that patients who have undergone bariatric surgery (bilio-pancreatic diversion) or
21 total laryngectomy and thyroidectomy could benefit from a liquid L-T4 formulation (20), which can
22 be administered directly through a feeding tube, with no need for an empty stomach. (21). Further,
23 along this line of reasoning, Brancato et al. suggested that a L-T4 oral solution consumed within 1
24 hour before breakfast could have an increased absorption rate in comparison to L-T4 tablets,
25 especially in the presence of other factors interfering with L-T4 absorption (22).

26 The main result of the present randomized, placebo-controlled, double-blind crossover trial
27 involving patients with previously untreated acquired hypothyroidism, clearly indicates that the

1 administration of the same dose of oral liquid levothyroxine either at breakfast or in fasting state,
2 30 minutes before breakfast, has indistinguishable effects on the thyroid hormonal profile. This
3 finding, coupled with the unanimous preference expressed by patients for taking the medication
4 directly at breakfast, may represent a distinct advantage of the liquid L-T4 formulation compared to
5 traditional L-T4 tablets, the absorption of which appears to be erratic when ingested together with
6 food and/or beverages, as reported by Perez and colleagues in a recent study (15). It is widely
7 accepted that adherence to medical recommendations, especially with regard to drug therapy, is
8 challenging (8), and well-documented cross-sectional surveys of patients taking levothyroxine
9 have shown that between 40% and 48% are either over-treated or under-treated (2,6). In
10 particular, a significant number of patients find it difficult to comply with L-T4 therapy as they have
11 to postpone their breakfast by 30-60 minutes (9).

12 Giusti et al. have recently reported that patients found the L-T4 tablet formulation more agreeable
13 than liquid ones (23). We can speculate that this is partly because tablets may be easier to
14 manage than vials, but it should also be considered that in the study by Giusti et al. the patients
15 added liquid L-T4 to a separate glass of water, with a relatively unpleasant taste when compared
16 to direct addition to usual breakfast beverages.

17 Our clinical observation with patients taking the drug mixed with coffee and other hot beverages
18 suggests that neither high temperatures (i.e., coffee, milk, cappuccino or hot tea), nor acidity (i.e.,
19 orange juice) alter the molecular properties or stability of L-T4. Studies on stability carried out with
20 tablet formulations have shown that sodium L-T4 rapidly degrades at 60-80°C (24,25); indeed, an
21 Italian 'espresso' coffee is served at similar temperatures (26). Very recently, Bernareggi et al.
22 have addressed this issue, demonstrating that liquid L-T4 is stable after 20 minutes in milk, tea,
23 coffee, and cappuccino at 50°C, as well as in orange juice at room temperature (27).

24 One important feature of our study is that it couples a rigorous study design to a real-life approach
25 in respect of usual breakfast habits and intake of drugs and supplements, which remained
26 unchanged throughout the study. Actually, no influence of breakfast composition or co-treatment
27 with other drugs (including PPI) on TSH levels was observed.

1 An important issue that has not been directly addressed by the present study is the question of
2 whether liquid L-T4 may have distinct advantages over tablet preparations in terms of clinical
3 outcomes, beyond timing of treatment. Negro et al. reported interesting data in this respect,
4 showing that administration of a liquid L-T4 formulation compared to tablets resulted in a
5 significantly higher number of hypothyroid patients who remained euthyroid over a 12-month
6 follow-up, with a significant reduction of variability in TSH values (28). We have also observed in a
7 retrospective series of 369 elderly hypothyroid patients treated with L-T4 over a five-year period
8 that the prevalence of subclinical or overt hyperthyroidism was significantly reduced in subjects
9 treated with liquid L-T4 compared to those treated with tablets (29). This is of particular interest in
10 elderly patients, where the increased risk of developing heart disease, osteoporosis, bone fracture
11 and cognitive impairment is well documented among subclinical hyperthyroid subjects (15, 30-33).
12 The liquid formulation is currently only available in Italy. This could represent a limitation, since all
13 the clinical studies have been conducted in this country, among people belonging to the same
14 ethnic group, with similar breakfast habits; accordingly, further studies performed in other
15 countries are needed.

16 In conclusion, the present study suggests that a liquid L-T4 formulation can be ingested directly at
17 breakfast, thus potentially improving therapeutic compliance. This observation is of considerable
18 clinical relevance, given that subjects who do not comply with L-T4 therapy requirements are more
19 likely to show variability in TSH concentrations and consequent unwanted effects.

20
21
22 Presented in part at the 84th Annual Meeting of the American Thyroid Association (ATA),
23 Coronado, California, October 29-November 2, 2014.

24 25 **Acknowledgments**

26 We thank the patients who volunteered to participate in this study.

1 **Author Disclosure Statement**

2 No conflicting financial interests exist.

1 REFERENCES

- 2
3 1. Vanderpump PJ, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley
4 Evans J, Hasan DM, Rodgers H, Tunbridge F, Young ET 1995 The incidence of thyroid
5 disorders in the community: a twenty-year follow-up of the Wickham Survey. Clin
6 Endocrinol (Oxf) 43:55-68.
- 7 2. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC 2000 The Colorado thyroid disease
8 prevalence study. Arch Intern Med 160:526-534.
- 9 3. Aoki Y, Belin RM, Clickner R, Jeffries R, Phillips L, Mahaffey KR 2007 Serum TSH and
10 total T4 in the United States population and their association with participant
11 characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002).
12 Thyroid 17:1211-1223.
- 13 4. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, Kim
14 BW, Peeters RP, Rosenthal MS, Sawka AM; American Thyroid Association Task Force
15 on Thyroid Hormone Replacement 2014 Guidelines for the treatment of hypothyroidism:
16 prepared by the American thyroid association task force on thyroid hormone replacement.
17 Thyroid 24:1670-751.
- 18 5. Vaidya B, Pearce SH 2008 Management of hypothyroidism in adults. BMJ 337:a801.
- 19 6. Parle JV, Franklyn JA, Cross KW, Jones SR, Sheppard MC 1993 Thyroxine prescription
20 in the community: serum thyroid stimulating hormone level assays as an indicator of
21 undertreatment or overtreatment. Br J Gen Pract 43:107-109.
- 22 7. Liwanpo L, Hershman JM 2009 Conditions and drugs interfering with thyroxine
23 absorption. Best Pract Res Clin Endocrinol Metab 23:781-792.
- 24 8. Düsing R, Lottermoser K, Mengden T 2001 Compliance with drug therapy-new answers
25 to an old question. Nephrol Dial Transplant 16:1317-1321.
- 26 9. Vita R, Saraceno G, Trimarchi F, Benvenga S 2013 A novel formulation of L-thyroxine (L-
27 T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet

1 formulations. *Endocrine* 43:154-160.

2 10. Cappelli C, Pirola I, Gandossi E, Formenti AM, Castellano M 2014 Oral liquid
3 levothyroxine at breakfast: a mistake? *Eur J Endocrinol* 170: 95-99.

4 11. Sanaka M, Urita Y, Yamamoto T, Shirai T, Kimura S, Aoyagi H, Kuyama Y 2013 Right
5 recumbent position on gastric emptying of water evidenced by (13)C breath testing. *World*
6 *J Gastroenterol* 21:362-365.

7 12. Wenzel KW, Kirschsieper HE 1997 Aspects of the absorption of oral L-thyroxine in normal
8 man. *Metabolism* 26:1–8.

9 13. Benvenga S, Bartolone L, Pappalardo MA, Russo A, Lapa D, Giorgianni G, Saraceno G,
10 Trimarchi F 2008 Altered intestinal absorption of L-thyroxine caused by coffee. *Thyroid*
11 18: 293-301.

12 14. Bach-Huynh TG, Nayak B, Loh J, Soldin S, Jonklaas J 2009 Timing of levothyroxine
13 administration affects serum thyrotropin concentration. *J Clin Endocrinol Metab* 94:3905–
14 3912.

15 15. Perez CL, Araki FS, Graf H, de Carvalho GA 2013 Serum thyrotropin levels following
16 levothyroxine administration at breakfast. *Thyroid* 23:779–784.

17 16. Liel Y, Harman-Boehm I, Shany S 1996 Evidence for a clinically important adverse effect
18 of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. *J*
19 *Clin Endocrinol Metab* 81:857–885.

20 17. Bell DS, Ovalle F 2001 Use of soy protein supplement and resultant need for increased
21 dose of levothyroxine. *Endocr Pract* 7:193–194.

22 18. Vita R, Fallahi P, Antonelli A, Benvenga S 2014 The administration of L-thyroxine as soft
23 gel capsule or liquid solution. *Expert Opin Drug Deliv* 11:1103-1111.

24 19. Vita R, Benvenga S 2014 Tablet levothyroxine (L-T4) malabsorption induced by proton
25 pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. *Endocr*
26 *Pract* 20: e38-41.

27 20. Pirola I, Formenti AM, Gandossi E, Mittempergher F, Casella C, Agosti B, Cappelli C

1 2013 Oral liquid L-Thyroxine (L-T4) may be better absorbed compared to L-T4 tablets
2 following bariatric surgery. *Obes Surg* 23:1493-1496.

3 21. Pirola I, Daffini L, Gandossi E, Lombardi D, Formenti A, Castellano M, Cappelli C 2014
4 Comparison between liquid and tablet levothyroxine formulations in patients treated
5 through enteral feeding tube. *J Endocrinol Invest* 37: 583-587.

6 22. Brancato D, Scorsone A, Saura G, Ferrara L, Di Noto A, Aiello V, Fleres M, Provenzano V
7 2014 Comparison of TSH Levels with Liquid Formulation Versus Tablet Formulations of
8 Levothyroxine in the Treatment of Adult Hypothyroidism. *Endocr Pract* 20:657-662

9 23. Giusti M, Mortara L, Machello N, Monti E, Pera G, Marenzana M 2015 Utility of a liquid
10 formulation of Levo-thyroxine in differentiated thyroid cancer patients. *Drug Res* 65:332-
11 336

12 24. Won CM 1992 Kinetics of degradation of levothyroxine in aqueous solution and in solid
13 state. *Pharmaceut Res* 9: 131-137.

14 25. Collier JW, Shah RB, Gupta A, Sayeed V, Habib MJ, Khan MA 2010 Influence of
15 formulation and processing factors on stability of levothyroxine sodium pentahydrate.
16 *AAPS PharmSci* 11: 818-825.

17 26. Andueza S, Maeztu L, Pascual L, Ibanez C, Paz de Pena M, Cid C 2003 Influence of
18 extraction temperature on the final quality of espresso coffee. *J Sci Food Agr* 83: 240-
19 248.

20 27. Bernareggi A, Grata E, Pinorini MT, Conti A 2013 Oral liquid formulation of levothyroxine
21 is stable in breakfast beverages and may improve thyroid patient compliance.
22 *Pharmaceutics* 5: 621–633.

23 28. Negro R, Valcavi R, Agrimi D, Toulis KA 2014 Levothyroxine liquid solution versus tablet
24 for replacement treatment in hypothyroid patients. *Endocr Pract* 1: 1-20.

25 29. Cappelli C, Pirola I, Daffini L, Gandossi E, Agosti B, Castellano M 2014 Thyroid hormonal
26 profile in elderly patients treated with two different levothyroxine formulations: A single
27 institute survey. *Eur Ger Med* 5: 382-385.

- 1 30. Rehman SU, Cope DW, Senseney AD, Brzezinski W 2005 Thyroid disorders in elderly
2 patients. *South Med J* 98:543–549.
- 3 31. Biondi B 2012 Natural history, diagnosis and management of subclinical thyroid
4 dysfunction. *Best Pract Res Clin Endocrinol Metab* 26:431–446.
- 5 32. Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G,
6 Åsvold BO, Sgarbi JA, Völzke H, Gencer B, Maciel RM, Molinaro S, Bremner A, Luben
7 RN, Maisonneuve P, Cornuz J, Newman AB, Khaw KT, Westendorp RG, Franklyn JA,
8 Vittinghoff E, Walsh JP, Rodondi N; Thyroid Studies Collaboration 2012 Subclinical
9 hyperthyroidism and the risk of coronary heart disease and mortality. *Arch Intern Med*
10 172:799–809.
- 11 33. Moon JH, Park YJ, Kim TH, Han JW, Choi SH, Lim S, Park do J, Kim KW, Jang HC 2014
12 Lower-but-normal serum TSH level is associated with the development or progression of
13 cognitive impairment in elderly: Korean Longitudinal Study on Health and Aging
14 (KLoSHA).. *J Clin Endocrinol Metab* 99:424–432.
- 15